Outlook: Zeneca has been slow to change
Tuesday 02 December 1997
However, as Zeneca yesterday defended itself against accusations that it has failed to respond quickly enough to market changes and has let its drug pipeline run dry, it is Zeneca, not ICI, which looks unable to throw off the shackles of its old corporate identity. While ICI, under ex-Unilever man Charles Miller Smith, has been busy reinventing itself, swapping at record speed commodities business for high-margin speciality chemicals, Zeneca looks like it has only just caught the boat on many market developments - biotechnology alliances, genomics, for example - which have turned its more aggressive competitors Glaxo Wellcome and SmithKline Beecham into world forces in the drug industry.
Not surprisingly Zeneca has been a much better investment than ICI. Over the past four years, shares in Zeneca have outperformed the market by almost 70 per cent, compared to a dismal 21 per cent underperformance from ICI. However the chemicals and drugs sectors naturally attract different share price ratings. Moreover, much of Zeneca's share price growth has been driven by bid speculation.
There aren't many medium-sized drug companies left to buy and in an industry where global consolidation makes sense, Zeneca has been a natural bid target. Unfortunately, potential buyers look in short supply. Roche has splashed much of its cash on other acquisitions and Glaxo would have to think hard about another hostile bid, given the disruption that integrating Wellcome caused. Without a bidder, Zeneca looks exposed. Though it tried hard yesterday to point out how many new products it had coming on line, most of what it has to offer are new versions of existing drugs rather than a full pipeline of late-stage products ready to launch.
Zeneca's main problem is management in general and the congenial Sir David Barnes in particular. Those who know the company talk of an English gentleman's club atmosphere where never a harsh word is raised. In the absence of a bidder, things plainly need to change.
Fracking is turning the US into a bigger oil producer than Saudi Arabia
Missing Malaysia Airlines plane: Details emerge of two young Iranians using stolen passports in search for a better life
Three-quarters of Britons are saying it wrong - the top ten most common mispronunciations
Oscar Pistorius trial: Athlete's friend asked him if 'he was f***ing mad' after shooting through sunroof
Oscar Pistorius trial: Forensic analyst says athlete 'was not wearing prosthetic legs' when he smashed locked toilet door with a bat
Britain's top vet sparks controversy with call for ban on slashing animals' throats in 'ritual' slaughters for halal and kosher meat products
Exclusive: Impact of immigrants on British workers ‘negligible’
Katie Hopkins continues campaign to become Britain's most hated talking head with poorly timed Bob Crow tweet
Grace Dent: Who cares if she spells it Barraco Barner? Gemma Worrall is more employable than some bookish arts graduate
Ukraine crisis: Russia pledges to 'retaliate against sanctions' as Ukrainian president says Crimea vote will not be recognised
The quiet diplomat: Catherine Ashton - recognised and admired in all the world’s troubled countries, yet ridiculed at home
- 1 Three-quarters of Britons are saying it wrong - the top ten most common mispronunciations
- 2 Boy George: Bad karma
- 4 First Kiss video: Filmmaker gets 20 strangers to make out on YouTube with awkward results
- 5 Ian Wright breaks down in ITV documentary charting his rise to Arsenal and England striker
iJobs Money & Business
£45000 - £55000 per annum + Bonus and Benefits: Harrington Starr: One of the i...
£57000 - £77000 per annum + Benefits: Pro-Recruitment Group: Top 10 Specialist...
£350 - £450 per day: Harrington Starr: Harrington Starr are currently working ...
£40000 - £60000 per annum: Harrington Starr: Application Support - FIX protoco...